key: cord-0961609-33xnt7zi
authors: Monaghan, A.; Jennings, G.; Xue, F.; Byrne, L.; Duggan, E.; Romero-Ortuno, R.
title: Orthostatic intolerance in adults with long COVID was not associated with postural orthostatic tachycardia syndrome
date: 2021-12-21
journal: nan
DOI: 10.1101/2021.12.19.21268060
sha: 2994d32694cce156499b48d77c0787268829df4c
doc_id: 961609
cord_uid: 33xnt7zi

In this observational cross-sectional study, we investigated predictors of orthostatic intolerance (OI) in adults with long COVID. Participants underwent a 3-minute active stand (AS) with Finapres NOVA, followed by a 10-minute unmedicated 70-degree head-up tilt test. 85 participants were included (mean age 46 years, range 25-78; 74% women), of which 56 (66%) reported OI during AS (OIAS). OIAS seemed associated with female sex, more fatigue and depressive symptoms, and greater inability to perform activities of daily living (ADL), as well as a higher heart rate (HR) at the lowest systolic blood pressure (SBP) point before the 1st minute post-stand (mean HRnadir: 88 vs 75 bpm, P=0.004). In a regression model also including age, sex, fatigue, depression, ADL inability, and peak HR after the nadir SBP, HRnadir was the only OIAS predictor (OR=1.09, 95% CI: 1.01-1.18, P=0.027). 22 participants had initial (iOH) and 5 classical (cOH) orthostatic hypotension, but neither correlated with OIAS. 71 participants proceeded to tilt, of which 28 had OI during tilt (OItilt). Of the 53 who had a 10-minute tilt, 7 (13%) fulfilled hemodynamic postural orthostatic tachycardia syndrome (POTS) criteria, but 6 did not report OItilt. OIAS was associated with a higher initial HR on AS, which after 1 minute equalized with the non-OIAS group. Despite these initial orthostatic HR differences, POTS was infrequent and largely asymptomatic. ClinicalTrials.gov Identifier: NCT05027724 (retrospectively registered on August 30, 2021).

Long COVID or post-COVID-19 syndrome first gained recognition among social support groups and 38 later in scientific and medical communities (Yong, 2021) . This condition is not well understood as it 39

affects COVID-19 survivors at all ages and levels of disease severity, with or without pre-existing 40 comorbidities, and regardless of hospitalisation status (Vanichkachorn et al., 2021; Yong, 2021 activities (Yan et al., 2021) . A systematic review reported that symptoms of mild COVID-19 may 44 persist after 3 weeks in a third of patients (van Kessel et al., 2021) . Another study reported that up to 45 one in four patients with mild COVID-19 were still experiencing symptoms after one year (Rank et 46 al., 2021); however, data on the exact prevalence and long-term effects of long COVID are still 47

lacking (Zarei et al., 2021) , with an urgent need for research in different populations and settings 48 (Michelen et al., 2021) . To aid clinicians and researchers, on 6 October 2021 the World Health 49

Organization (WHO) issued a clinical case definition of post COVID-19 condition, obtained by a 50

Delphi consensus (WHO, 2021), as follows: "Post COVID-19 condition occurs in individuals with a 51 history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of 52 COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative 53 diagnosis. Common symptoms include fatigue, shortness of breath, cognitive dysfunction but also 54 others, which generally have an impact on everyday functioning. Symptoms may be new onset, 55

following initial recovery from an acute COVID-19 episode, or persist from the initial illness. 56

Symptoms may also fluctuate or relapse over time". 57

The neurological and cardiovascular overlap in some long COVID symptoms, and in particular the Ireland. The study received full ethical and regulatory approvals. For the reporting, we followed 73 STROBE guidelines (von Elm et al., 2007) . 74

Participants were eligible for inclusion under all the following criteria: (1) age 18 years or older; (2) 75 history of confirmed or suspected SARS-CoV-2 infection; (3) experiencing prolonged symptoms 76 such as fatigue; (4) able to mobilise independently (with or without aid); (5) able to transfer 77 independently or with minimal assistance of one person from lying to standing; and (6) able to give 78 informed consent. 79 Participants were recruited from the following sources in our hospital: (1) falls and syncope unit; (2) 80 geriatric day hospital; (3) post COVID-19 outpatient clinic; (4) staff who had contracted COVID-19;  81  and (5) participants from earlier post-COVID-19 research who had consented to be contacted for  82 further studies. In addition, we also considered (6) self-referrals. COVID-19 and non-COVID-19  83  exclusion criteria for enrolment are outlined in the Supplementary Information (section 1) . 84

Prior to enrolment, participants were provided with a Participant Information Leaflet explaining the 85 aims and procedures of the study. All participants provided explicit, informed, and voluntary consent 86

to partake in the study, were explained the benefits and risks of participating in the research, and had 87 the opportunity to discuss the study and ask questions. Participants were given the opportunity to 88 withdraw from the study at any point and to forego completing components of the assessment 89 protocol as desired. 90 For the active stand, participants underwent a lying-to-standing orthostatic test with non-invasive 98 beat-to-beat blood pressure monitoring using digital photoplethysmography (Finapres® NOVA, 99

Finapres Medical Systems, Amsterdam, The Netherlands). The height correction unit was zeroed and 100

implemented as per manufacturer's specifications. A 5-lead continuous electrocardiogram (ECG) was 101 acquired throughout the test. During the supine rest period, an oscillometric brachial blood pressure 102 measurement was obtained from the non-monitored (right) arm for calibration purposes, once the 103

PhysioCal repetition rate was 70 beats or more (Wesseling, 1996) . After at least 5 minutes of 104 uninterrupted supine rest, a total lying duration of no more than 10 minutes, and a 10-second 105 countdown, participants were asked to stand, unaided, as quick as possible. The PhysioCal was 106 turned off just before the stand and switched back on at 1-minute post-stand. After standing, SBP, 107 DBP, and HR were monitored for three minutes. Throughout the recording, participants were asked 108 to remain motionless and in silence with the monitored arm (left) resting extended by the side, except 109

for reporting any symptoms of concern. Immediately after the stand, and at the end of the test, 110

participants were asked to report whether they had felt any symptoms of dizziness, light-headedness, 111 or any other abnormal symptoms. 112

For the tilt procedure, which was medically supervised and started after a brief non-monitored break 113

following AS, participants were affixed to an electrically motorized tilt table with footboard support  114 and approximately 10 seconds of travel time between 0° and 70° (Agasan KT-1060/E, AGA  115 Sanitätsartikel GmbH, Löhne, Germany). Throughout the tilt, participants underwent Finapres® 116 NOVA monitoring (with PhysioCal on and continuous ECG monitoring) during an initial period of 117 uninterrupted supine rest of at least 5 minutes (with a total lying duration of no more than 10 118 minutes) and a subsequent head-up tilt to 70° for 10 minutes or until symptoms developed. An 119 oscillometric brachial blood pressure was also obtained during supine rest. During the head-up tilt 120 phase, participants were asked to report whether they felt any symptoms of dizziness, light-121 headedness, or any other abnormal symptoms, at which point participants were offered to be tilted 122 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint 

We computed the maximum HR between nadir and minutes 1 to 10 (or the available minutes in case 159 of early tilt termination), to which we subtracted baseline HR, and POTS was defined in 160 hemodynamic terms as a difference of ≥ 30 bpm in the absence of cOH tilt (Freeman et al., 2011). 161

For the characterisation of the cohort, we collected measures including: 163 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 21, 2021. ; https://doi.org/10.1101/2021.12.19.21268060 doi: medRxiv preprint • Demographics: age, sex. 164

• Anthropometrics: body mass index (Kg/m 2 ). 165

• Proportion of third level education (i.e., primary university degree or higher). 166

• Past medical history including previous or current smoker, hypertension, heart disease (e.g., 167

previous heart attack, angina, congestive heart failure, atrial fibrillation), diabetes mellitus (yes or 168 no). 169

• Current medications including being on an antihypertensive, beta blocker, antidepressant, or 170 benzodiazepine (yes or no). 171

• COVID-19 history: date of COVID-19 diagnosis; hospitalisation status (at least 1 overnight stay: 172 yes or no); current symptomatology (from a structured questionnaire including 41 possible 173 symptoms: yes or no for each), and interference with activities of daily living (ADL) ("In the past 174 month, I have had too little energy to do the things I wanted to do": yes or no). 175

• The 11-item Chalder Fatigue Scale (CFQ), a self-rating scale developed to measure the severity 176 of physical and mental fatigue (Cella and Chalder, 2010). We employed the Likert scoring 177 system, with an overall scale range from 0 (minimum) to 33 (maximum fatigue). 178

• The 20-item Center for Epidemiological Studies Depression (CES-D) scale (Radloff, 1977) . 179

Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. 180

• In terms of the haemodynamic comparison between OI AS and non-OI AS subgroups ( In the logistic regression model to investigate predictors of OI AS ( follows: "slightly light-headed" (n=10, 35.7%), "light-headed" (n=8, 28.6%), "slightly dizzy" (n=3, 346 10.7%), "dizzy" (n=2, 7.1%), "very light-headed" (n=1, 3.6%), "head spinning" (n=1, 3.6%), 347

"drained" (n=1, 3.6%), "weak" 1 (n=1, 3.6%), and "palpitations" (n=1, 3.6%). No instances of 348 arrhythmia or acute myocardial ischemia were detected in the continuous ECG trace. As regards OI 349 agreement between AS and tilt, 78.6% (n=22) of those who had OI tilt had previously reported OI AS 350 (P=0.020). 18 of the 71 participants had an early tilt termination due to symptoms (n=2 before the 2 nd 351 minute, n=3 before the 3 rd minute, n=1 before the 4 th minute, n=2 before the 5 th minute, n=5 before 352 the 6 th minute, n=2 before the 8 th minute, and n=3 before the 10 th minute). Of all the early 353 terminations, 13 (72.2%) were terminated because of OI tilt symptoms (P=0.001). The other 5 early tilt 354

terminations were due to the development of "slight shortness of breath" (n=1), "feet pain" (n=1) and 355

for reasons not related to development of symptoms (n=3 OI AS , 2 were on beta blockers, and 1 on antihypertensives. In the 18 participants whose tilt was 364 terminated early, none of the available data fulfilled POTS criteria. As shown in the Supplementary 365

Information, there were no statistically significant differences between OI tilt subgroups across other 366 clinical (section 2) or haemodynamic characteristics (sections 3 and 4), and no significant predictors 367 of OI tilt in the regression model (section 5). 368 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In this study, we investigated predictors of orthostatic intolerance (OI) in adults with long COVID. 370

OI during active stand (OI AS ) was reported by 66% of our sample and seemed associated with female 371 sex, more fatigue and depressive symptoms, and greater inability to perform activities of daily living, 372 as well as a higher heart rate at the lowest systolic blood pressure point before the first minute post-373 stand (HR nadir ). In a regression model also including age, sex, fatigue, depression, ADL inability, and 374 peak HR after the nadir SBP, HR nadir was the only OI AS predictor. 26% of participants had initial and 375 6% classical orthostatic hypotension, but neither correlated with OI AS . Of the participants who had a 376 tilt, 39% had OI during tilt; and of the participants who completed a 10-minute tilt, 13% fulfilled 377 hemodynamic POTS criteria, but most cases (6 out of 7) were asymptomatic. 378 379

The HR at the time of nadir SBP after stand seemed more important than the peak HR after the nadir 380 SBP as a predictor of OI AS . In this light, findings might reflect different baroreceptor-related HR 381 responses in participants with OI AS , possibly due to lower efferent vagus nerve activity, and/or higher 382 sympathetic activation. In this regard, it has been described that with incomplete loss of baroreflex 383 afferents, a mild syndrome of orthostatic tachycardia or orthostatic intolerance may appear; in some 384 cases, it may primarily reflect interruption of efferent right vagus nerve activity, leading to a loss of 385 parasympathetic input to the sinus node, with a consequent increase in heart rate; and in other cases, 386 mild sympathetic activation may occur with stress and provoke tachycardia disproportionate to the 387 increase in blood pressure ( though orthostatic hypertension did not seem related to OI in our cohort, it has been described that 415 some patients with chronic OI develop symptoms despite a hypertensive response to standing, 416 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 21, 2021. ; https://doi.org/10.1101/2021.12.19.21268060 doi: medRxiv preprint suggesting that the symptoms of chronic OI may somehow be elicited by central responses to the 417 inappropriate tachycardia, even in the absence of any actual reduction in perfusion pressure 418 (Narkiewicz and Somers, 1998 In conclusion, in our study OI AS was associated with a higher initial HR on AS, which after 1 minute 457 equalized with the non-OI AS group, and POTS was infrequent and largely asymptomatic. The burden 458 of psychological symptoms in this cohort was high and findings may be related to interoceptive 459 mechanisms. However, more research is required to understand the mechanisms and long-term 460 prognosis of autonomic function in long COVID, to better delineate therapies and estimate the need 461 for services. 462 463 464 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Circulation 105, 2518-2523. 554 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 21, 2021. ; https://doi.org/10.1101/2021.12.19.21268060 doi: medRxiv preprint

Long COVID, a 487 comprehensive systematic scoping review

Causation or confounding: why controls are critical 489 for characterizing long COVID

Clinical 491 characterization of dysautonomia in long COVID-19 patients

Anticipating the long-term cardiovascular effects of COVID-19

Autonomic dysfunction in SARS-COV-2 infection acute and long-term 495 implications COVID-19 editor's page series

Postural orthostatic tachycardia syndrome (POTS) and other 497 autonomic disorders after COVID-19 infection: a case series of 20 patients

Diagnosing orthostatic hypotension with continuous and interval 501 blood pressure measurement devices

Depression pandemic and cardiovascular risk in the COVID-19 era and long COVID 504 syndrome: gender makes a difference

SARS-CoV-2 and nervous system: From pathogenesis to clinical manifestation

The Dysfunction is in the Details: Neurovascular Changes in COVID-19

Preparing for the long-haul: Autonomic 560 complications of COVID-19

Autonomic 562 balance determines the severity of COVID-19 courses

Center for Epidemiologic 564 Studies Depression Scale (CES-D) as a screening instrument for depression among 565 community-residing older adults

More than 50 long-term effects of COVID-19: a systematic review 568 and meta-analysis

Characterising long COVID: 572 a living systematic review

Is postural tachycardia syndrome in the head or in the heart? 574 And other updates on recent autonomic research

A case report of 576 postural tachycardia syndrome after COVID-19

Test-Retest Reliability of Five Times Sit 579 to Stand Test (FTSST) in Adults: A Systematic Review and Meta-Analysis

Chronic orthostatic intolerance: part of a spectrum of 582 dysfunction in orthostatic cardiovascular homeostasis?

COVID-19-induced postural orthostatic 584 tachycardia syndrome treated with ivabradine

Clinical and Laboratory

Hyperadrenergic Postural Orthostatic Tachycardia Syndrome (POTS) after COVID-19

Emotional orienting during 589 interoceptive threat in orthostatic intolerance: Dysautonomic contributions to psychological 590 symptomatology in the postural tachycardia syndrome and vasovagal syncope

Long COVID-19: A Primer for Cardiovascular 596 Health Professionals, on Behalf of the CCS Rapid Response Team

Baroreceptor reflex and integrative stress responses in chronic fatigue syndrome

COVID-19 602 pandemic related long-term chronic stress on the prevalence of depression and anxiety in the 603 general population

The CES-D scale: A self report depression scale for research in the general 605 population

Long-COVID postural 608 tachycardia syndrome: an American Autonomic Society statement

One Year 612 after Mild COVID-19: The Majority of Patients Maintain Specific Immunity, But One in Four 613 Still Suffer from Long-Term Symptoms

Neurology and neuropsychiatry of COVID-19: a 619 systematic review and meta-analysis of the early literature reveals frequent CNS 620 manifestations and key emerging narratives

Long-Term 622 Impact of COVID-19: A Systematic Review of the Literature and Meta-Analysis

Biomedicines 9

Long COVID and 626 Post-infective Fatigue Syndrome: A Review

Managing the long term effects of 628 covid-19: summary of NICE, SIGN, and RCGP rapid guideline

Autonomic dysfunction following COVID-19 infection: an 632 early experience

Autonomic function test during the 634 COVID-19 pandemic: the Stanford experience

Fatigue following COVID-19 infection is not associated with autonomic dysfunction

Measuring orthostatic hypotension with the Finometer device: is a blood pressure drop of one 640 heartbeat clinically relevant?

Post-acute 642 and long-COVID-19 symptoms in patients with mild diseases: a systematic review

Post-COVID-19 Syndrome (Long Haul Syndrome): 646 Description of a Multidisciplinary Clinic at Mayo Clinic and Characteristics of the Initial 647 Patient Cohort

The Strengthening the Reporting of Observational Studies

STROBE) statement: guidelines for reporting observational studies

Finger arterial pressure measurement with Finapres

A clinical case definition of post COVID-19 condition by a Delphi consensus: 6 655

Post_COVID-19_condition-Clinical_case_definition

Initial 658 orthostatic hypotension: review of a forgotten condition

Diastolic orthostatic hypertension 660 and cardiovascular prognosis in type 2 diabetes: a prospective cohort study

Long COVID-19 Syndrome: A Comprehensive Review of 663 Its Effect on Various Organ Systems and Recommendation on Rehabilitation Plans

Biomedicines 9

Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk 666 factors, and treatments

Long-term 668 side effects and lingering symptoms post COVID-19 recovery

We are very grateful to our participants for their involvement in the study. 484 9

The authors declare that the research was conducted in the absence of any commercial or financial 466 relationships that could be construed as a potential conflict of interest. 467 The funder had no role in the conduct of the research and/or preparation of the article; in study 480 design; in the collection, analysis, and interpretation of data; in writing of the report; or in the 481 decision to submit the paper for publication. 482 8